Table 3.
Comparison of presenting clinical and laboratory findings according to the applied therapy of patients with t-APL
| Characteristics | CTX/ATRA n = 53 | ATO/ATRA n = 24 | CTX/ATO/ATRA n = 19 | ATRA only n = 7 | P-value |
|---|---|---|---|---|---|
| Age, years | |||||
| Median | 57.0 | 60.0 | 56.0 | 69.6 | 0.002 |
| Range | 19.6–80.0 | 24.0–79.1 | 18.0–79.0 | 64.0–73.0 | |
| Gender, no. (%) | |||||
| Male | 13 (25) | 6 (25) | 10 (53) | 4 (57) | 0.5 |
| Female | 40 (75) | 18 (75) | 9 (47) | 3 (43) | |
| WBC, ×109/l | |||||
| Median | 1.9 | 1.9 | 1.6 | 4.5 | 0.86 |
| Range | 0.3–145 | 0.3–57.2 | 0.2–126 | 0.6–75.1 | |
| Missing | 4 | 1 | – | – | |
| Hemoglobin, g/dl | |||||
| Median | 10.1 | 9.3 | 9.7 | 9.3 | 0.88 |
| Range | 4.9–13.8 | 3.8–13.2 | 6.8–13.5 | 8.4–13.5 | |
| Missing | 3 | 1 | – | – | |
| Platelet count, ×109/l | |||||
| Median | 36 | 34 | 24 | 11 | 0.009 |
| Range | 12–220 | 12–121 | 9–103 | 3–72 | |
| Missing | 4 | 1 | – | – | |
| Percentage of PB blasts | |||||
| Median | 2 | 35 | 6 | 35 | 0.16 |
| Range | 0–94 | 0–81 | 0–86 | 2–76 | |
| Missing | 25 | 10 | 2 | 1 | |
| Percentage of BM blasts | |||||
| Median | 70 | 80 | 72 | 80 | 0.87 |
| Range | 2–95 | 0–94 | 8–95 | 79–90 | |
| Missing | 19 | 3 | 1 | 3 | |
| LDH value, U/l | |||||
| Median | 274 | 303 | 255 | 387 | 0.48 |
| Range | 124–1654 | 147–1112 | 139–2320 | 262–675 | |
| Missing | 23 | 5 | 2 | 0 | |
| Risk categorizationa no. (%) | |||||
| Low/Intermediate | 39 (80) | 21 (88) | 15 (79) | 5 (71) | 0.63 |
| High | 10 (20) | 3 (12) | 4 (21) | 2 (29) | |
| Missing (no.) | 4 | – | – | – | |
| Cytogenetics, no. (%) | |||||
| t(15;17) sole | 34 (77) | 12 (57) | 13 (87) | 3 (75) | 0.20 |
| t(15;17) & additional abn | 10 (23) | 9 (43) | 2 (13) | 1 (25) | |
| Missing (No.) | 9 | 3 | 4 | 3 | |
| FLT3-ITD, no. (%) | |||||
| Mutated | 7 (26) | 6 (43) | 5 (71) | 2 (66) | 0.10 |
| Unmutated | 20 (74) | 8 (57) | 2 (29) | 1 (33) | |
| Missing (no.) | 26 | 10 | 12 | 4 | |
| FAB, no. (%) | |||||
| M3 | 49 (94) | 20 (87) | 19 (100) | 6 (86) | 0.23 |
| M3 variant | 3 (6) | 3 (13) | – | 1 (14) | |
| Missing (no.) | 1 | 1 | – | – | |
| Extramedullary disease no. (%) | |||||
| Yes | – | 23 (100) | 17 (90) | 7 (100) | 0.12 |
| No | 40 (100) | – | 2 (10) | – | |
| Missing (no.) | 13 | 1 | – | – | |
Abbreviations: abn, abnormality; ATO, arsenic trioxide; ATRA, all-trans retinoic acid; BM, bone marrow; CTX, chemotherapy; FAB, French-American-British; ITD, internal tandem duplication; LDH, serum lactate dehydrogenase; No, number; PB, peripheral blood; t-APL, therapy-related acute promyelocytic leukemia; WBC, white blood counts.
a
Risk categorization based on WBC at diagnosis (low/intermediate-risk: WBC < 10.0 G/l; high-risk: WBC ≥ 10.0 G/l). Percentages may not add to 100 because of rounding.